China’s Sinopharm vaccine may offer weak COVID-19 protection for elderly, says study

China’s Sinopharm vaccine may offer weak COVID-19 protection for elderly, says study
·4 min read

A survey of blood samples taken from 450 people in Hungary at least two weeks after their second Sinopharm dose found that 90% under 50 years old developed protective antibodies. But the percentage declined with age, and 50% of those over 80 had none.

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting